Results 111 to 120 of about 219,082 (266)

Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor

Infectious Diseases and Therapy
Introduction Ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, shows efficacy and safety in participants with mild to moderate COVID-19.
Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota   +3 more
doaj   +1 more source

The heterogeneity among subgroups of haplogroup J influencing Alzheimer’s disease risk

Journal of Advanced Research, 2021
Introduction: The impact of mitochondrial haplogroups on Alzheimer’s disease (AD) risk has not been fully elucidated and warrants further investigation at the subgroup level.
HaoChen Liu, Yixuan Zhang, Huimin Zhao, Yanan Du, XiaoQuan Liu   +4 more
doaj  

Optimal designs for random effect models with correlated errors with applications in population pharmacokinetics [PDF]

, 2009
We consider the problem of constructing optimal designs for population pharmacokinetics which use random effect models. It is common practice in the design of experiments in such studies to assume uncorrelated errors for each subject.
Dette, Holger, Holland-Letz, Tim, Pepelyshev, Andrey   +2 more
core   +6 more sources

Kidney Fibrosis In Vitro and In Vivo Models: Path Toward Physiologically Relevant Humanized Models

Advanced Healthcare Materials, EarlyView.
This review discusses kidney diseases with a focus on kidney fibrosis and the models currently used. It highlights the limitations of animal and 2D in vitro models in replicating human kidney anatomy and physiology. Consequently, there is a significant need for humanized 3D in vitro models, such as 3D cell aggregates, membranes and hydrogels, on‐chip ...
Gabriele Addario, Lorenzo Moroni, Carlos Mota   +2 more
wiley   +1 more source

The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling

Journal of Immunology Research, 2015
Therapeutic protein products (TPP) have been widely used to treat a variety of human diseases, including cancer, hemophilia, and autoimmune diseases. However, TPP can induce unwanted immune responses that can impact both drug efficacy and patient safety.
Liusong Yin, Xiaoying Chen, Abhinav Tiwari, Paolo Vicini, Timothy P. Hickling   +4 more
doaj   +1 more source

Reservoir‐Type Subcutaneous Implantable Devices Containing Porous Rate Controlling Membranes for Sustained Delivery of Risperidone

Advanced Healthcare Materials, EarlyView.
This study presents a novel implantable drug delivery systemwith a biodegradable poly(caprolactone) membrane and compressed drug core forsustained release. These implantable devices deliver risperidone in vitro for 170 days and in vivo for 49 days in rats, showing promise for chronic conditions like schizophrenia.
Linlin Li, Andi Dian Permana, Juan Domínguez‐Robles, Muh Nur Amir, Habibie Habibie, Qonita Kurnia Anjani, Li Zhao, Natalia Moreno‐Castellanos, Ryan F Donnelly, Eneko Larrañeta   +9 more
wiley   +1 more source

Development of a SARS‐CoV‐2 viral dynamic model for patients with COVID‐19 based on the amount of viral RNA and viral titer

CPT: Pharmacometrics & Systems Pharmacology
The target‐cell limited model, which is one of the mathematical modeling approaches providing a quantitative understanding of viral dynamics, has been applied to describe viral RNA profiles of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐
Daichi Yamaguchi, Ryosuke Shimizu, Ryuji Kubota   +2 more
doaj   +1 more source

Pharmacokinetic–pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida [PDF]

, 2018
A calf tissue cage model was used to study the pharmacokinetics (PK) and pharmacodynamics (PD) of oxytetracycline in serum, inflamed (exudate) and noninflamed (transudate) tissue cage fluids.
Aliabadi, Aliabadi, Aliabadi, Brentnall, Craig, Davey, de Jong, Deleforge, El Korchi, Esaki, Frimodt-Moller, Higgins, Illambas, Laven, Lees, Lees, Lees, Lees, Lees, Martinez, Martinez, Mestorino, Morck, Mouton, Mouton, Musser, Nielsen, Nouws, Nouws, Nouws, Nouws, O'Connor, Papich, Papich, Portis, Schentag, Sidhu, Sidhu, Toutain, Toutain, Toutain, Toutain, Toutain, Toutain, Turnidge, Yamaoka   +45 more
core   +1 more source

Longer Acting Injectable: Continuous, Linear Release of a Progestin Contraceptive From an Oxidized Porous Silicon Host

Advanced Healthcare Materials, EarlyView.
Progestin drugs are loaded into a mesoporous silicon dioxide host by melt‐infiltration. Drugs that decompose at or close to their melting point can be loaded by the addition of cholesterol, which acts as a melting point suppressor. High mass loading of the drug is achieved, and dissolution of the composite is controlled by the nanoscale properties of ...
Geoffrey Hollett, Ruhan Fan, Tushar Kumeria, Heidi Leonard, Byungji Kim, Taylor R. Martin, Irmak Ipekci, Joanna Wang, Jiuk Byun, Nicole A. Chan, Amber Pierron, Curtis E. Moore, Jennifer Ayres, Michael J. Sailor   +13 more
wiley   +1 more source

A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study

BMC Nephrology, 2019
Background Approximately 30% of patients on dialysis received combination therapy for their phosphate binder prescription; however, few studies for combined effects of phosphate binders are reported.
Atsushi Yaguchi, Kenji Akahane, Kumi Tsuchioka, Saori Yonekubo, Shota Yamamoto, Yasuaki Tamai, Satoshi Tatemichi, Hiroo Takeda   +7 more
doaj   +1 more source